Atopic Dermatitis

Ruth Ann Vleugels, MD, MPD, MBA, provides important considerations for clinicians when reflecting upon the safety of oral Janus Kinase (JAK) inhibitors and traditional systemic immunosuppressants.

Trinity Flint shares her experience using upadacitinib to treat atopic dermatitis and the impact it has had on her quality of life.

Diego Ruiz Dasilva, MD, FAAD, shares treatment approaches to atopic dermatitis, focusing on medications such as dupilumab and upadacitinib.

Patients given LNK01001 showed significant improvement in EASI scores over placebo.

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Christopher Bunick, MD, PhD, presents the results of the long-term four-year safety study of upadacitinib as treatment for atopic dermatitis (AD).

Leading atopic dermatitis experts delve into integrative approaches, prescription options, and strategies to encourage patients to stick with their treatment plan.

Trinity Flint reviews the topical treatments she was prescribed in the early stages of atopic dermatitis and her response to treatment.

A dermatologist and a patient discuss the importance of having a multidisciplinary team approach to treating atopic dermatitis.

Researchers found that the Comfiknit Atopic Eczema T-shirt reduced Eczema Area and Severity Index scores.

Peter Lio, MD, discusses pearls and takeaways from the atopic dermatitis panel he participated in at the 2023 Society of Pediatric Dermatology meeting.

Diego Ruiz Dasilva, MD, FAAD, and Trinity Flint discuss early treatment of her atopic dermatitis, focusing on topical treatment.

Trinity Flint comments on the burden of atopic dermatitis, highlighting its impact on her social life as a child and teen.

Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.

Ruth Ann Vleugels, MD, MPD, MBA, and Christopher Bunick, MD, PhD, provide their clinical experience with Janus Kinase (JAK) inhibitors and the importance of patient compliance with these agents.

Researchers found that treatment for atopic dermatitis could contribute to a higher mutation rate.

Grant applications are open from now until August 24, 2023, with an anticipated project start/end date of January 2024 through July 2025.

Diego Ruiz Dasilva, MD, FAAD, reviews the difference between clinical presentation of atopic dermatitis in adults vs children, as well as the pathophysiology of the disease.

Trinity Flint, a patient with atopic dermatitis, talks about the initial symptoms she had as a child that led her to see a doctor for diagnosis.

Compared to patients who identified as heterosexual, patients in the LGBTQ+ community have a higher prevalence of atopic dermatitis, asthma, and allergic rhinitis.

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Researchers conducted a systematic review and meta-analysis of probiotic treatment efficacy in children with atopic dermatitis.

Clinicians James Q. Del Rosso, DO; Raj Chovatiya, MD, PhD; and Lisa Swanson, MD, PhD, review the study, “Rapid Pruritus Reduction With Ruxolitinib Cream in Patients With Atopic Dermatitis."

Experts discuss prospective therapies on the horizon for atopic dermatitis (AD).